SAN DIEGO, Aug. 08, 2018 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2018 and provided an update on its corporate activities and product pipeline. "The financing commitments we secured in the second quarter provide significant funding for the company, including support for the Phase 3 clinical trials of rezafungin for the treatment of candidemia and invasive candidiasis…

Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Dr. Taylor Sandison, chief medical officer, will present clinical efficacy and safety data for the company's lead antifungal rezafungin for the treatment and prevention of invasive fungal infections at two upcoming, global infectious disease conferences. Abstracts highlighting rezafungin data have…

Four accepted presentations include a late-breaker featuring Phase 2 STRIVE trial data and three posters describing the activity of rezafungin against fungal pathogens SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present four posters highlighting data from preclinical studies and a clinical trial of rezafungin, its lead antifungal product candidate, at the American Society for Microbiology (ASM) Microbe 2018, being held June 7-11…

New Partnership to Jointly Conduct Preclinical Development of Cidara's Cloudbreak Antibody-Drug Conjugates SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it and Rutgers University have been awarded a five-year, $5.5 million partnership grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services. The…

SAN DIEGO, May 21, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with certain investors providing for the purchase and sale, in a registered direct offering, of up to an aggregate of $120.0 million of its common stock, in three closings. Cidara will offer 10,638,297 shares of common stock in the first closing of the offering at a…

SAN DIEGO, May 10, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and provided an update on its corporate activities and product pipeline. "The first quarter of 2018 marked a significant step forward for Cidara. We reported positive topline results from our STRIVE Phase 2 clinical trial, and continued outreach to the medical and scientific communities with…

Company secures four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its lead antifungal rezafungin will be presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Madrid, Spain, April 21-24, 2018. "At…

Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms Definitive Phase 1 QT clinical trial showed no cardiac abnormalities SAN DIEGO, March 21, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today is providing additional details from the positive safety and efficacy findings in the Phase 2 STRIVE trial relating to the principal investigators' efficacy assessments of programmatic indeterminate patients…

Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections Phase 3 studies for both treatment and prevention on track to start mid-2018 Company to host conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 19, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported positive topline results from the global, randomized Phase 2 STRIVE clinical trial of its lead…

SAN DIEGO, March 08, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted for presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Lisbon, Portugal, March 18-21, 2018. Rezafungin acetate is a novel antifungal echinocandin and is the only once-weekly product candidate in development for the treatment and prevention of…